Edition:
United States

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

0.99USD
10:41am EDT
Change (% chg)

$-0.01 (-1.00%)
Prev Close
$1.00
Open
$1.00
Day's High
$1.00
Day's Low
$0.99
Volume
9,759
Avg. Vol
26,864
52-wk High
$2.17
52-wk Low
$0.92

ARQL.OQ

Chart for ARQL.OQ

About

ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $71.15
Shares Outstanding(Mil.): 71.15
Dividend: --
Yield (%): --

Financials

  ARQL.OQ Industry Sector
P/E (TTM): -- 58.07 30.12
EPS (TTM): -0.33 -- --
ROI: -85.96 0.23 13.28
ROE: -85.96 6.18 14.44

BRIEF-ArQule receives clearance of IND application from the FDA for proprietary reversible BTK inhibitor, ARQ 531

* ArQule receives clearance of investigational new drug application from the FDA for proprietary reversible BTK inhibitor, ARQ 531

Apr 11 2017

BRIEF-Arqule trial did not meet its primary endpoint of progression free survival

* Trial did not meet its primary endpoint of progression free survival (pfs).

Mar 27 2017

BRIEF-Arqule posts Q4 loss per share of $0.10

* Arqule reports fourth quarter and full year 2016 financial results

Mar 07 2017

BRIEF-Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial

* Daiichi Sankyo and Arqule announce the completion of the metiv-hcc phase 3 study of tivantinib in second-line treatment of met-overexpressing hepatocellular carcinoma

Feb 17 2017

BRIEF-Arqule Q3 loss $0.08/shr

* Q3 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Nov 07 2016

More From Around the Web

Earnings vs. Estimates